metastatic/advanced hepatocellular cancer (mHCC) | |
mHCC - (neo)adjuvant (NA) | |
atezolizumab based treatment | |
atezolizumab plus bevacizumab | IMbrave050 |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-